Hey Ryan, do you think reconfiguring next year’s vaccine formula to handle BA.3.2 will be as effective as the current vaccines have been for past saltations?

Or is there something “new”-new BA.3.2 has up its sleeve that would make things less straight forward?

(ie new binding affinities or w/e)

I know this is a broad question and maybe hard to answer as we’ve come a long way with testing since 2019,

But do you have any insights to how seasonal coronaviruses have been impacted by the introduction of SARS-CoV-2?

i.e. certain strains were dampened, cross immunity caused X or Y, etc

It’s nuts we don’t have at least another antiviral like Xocova approved

While I don’t expect better efficacy than Paxlovid, at least these other similar meds in the pipeline don’t have the same significant drug interactions

Anyway, MOV should absolutely be removed from the market, imo

It was so obvious when molnupiravir hit the market that it was potentially dangerous (liiiiterally MOA of creating mutations)

You’d think for something risky like MOV, there’d at least be an upside

But even the initial efficacy estimates were unreasonably low…

That totally makes sense.

And thanks again for all the work you do!! Invaluable. Especially these days.

It’s criminal that funding for all other research has been cancelled,

Yet HHS is calling for…

Monovalent vaccines for components of MMR…?

My gosh.

It’s one thing to have more options. That’s fine.

But not when we have actual health issues to research… 🙄

Meant to add — given there would be no “practical” implications for rhinovirus testing (ie no treatment protocol specific to it / antivirals like for the flu or covid),

That’s even more reason to suspect an increasingly discretionary / selected testing of rhinovirus, no?

Please correct me if I’m mistaken in these assumptions and their potential impact on the interpretation of the graph(!)

I don’t mean to contradict anything you had said in your posts — just trying to think through it a bit / mention my first thoughts

Given that the graph is based on test positivity percentage,

Testing for Covid is much more readily available / widespread than testing for rhinovirus

And given rhinovirus is less serious than Covid, it’s probably only tested for after ruling out Covid and flu

So magnitudes are hard to compare

If you’re referring to the mRNA from vaccination, they are short lived and do not have the capability to replicate.

You’re injected with a set amount and that’s the max number of cells capable of having the ribosome ingest & convert.

And any given cell does not live forever — lifespan is short *

oh my gosh, I thought the "It is the sense of the committee" verbiage was completely ridiculous too!

I thought to myself "ok, it's possible this is standard so don't call it out without checking last year's" — which I didn't care enough to

So I'm very glad you mentioned it.

Such a cruel joke.

We dodged a huge bullet then?

This is thanks to the outcry from everyone in the community and advocates like yourself.

Thank you to everyone who took this seriously and spoke out

I realized this morning that it's easier to get a firearm in Georgia than it is to get a COVID vaccine.

Very disappointed in this state right now

Sadly, we could’ve had this falls vaccine configured for XFG back during the FDA strain meeting

Blah

Ty for this post though — provides good insight